checkAd

    Basilea Pharmaceutica AG  441  0 Kommentare Continued strong Cresemba (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea - Seite 2

    About Basilea

    Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

    Disclaimer

    This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

    For further information, please contact:

    Peer Nils Schröder, PhD
    Head of Corporate Communications & Investor Relations
    +41 61 606 1102
    media_relations@basilea.com
    investor_relations@basilea.com

    This press release can be downloaded from www.basilea.com.

    References

    1     Cresemba U.S. prescribing information [Accessed: December 07, 2018]

    2     The registration status and approved indications may vary from country to country.





    This announcement is distributed by West Corporation on behalf of West Corporation clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Basilea Pharmaceutica AG via Globenewswire

    --- End of Message ---

    Basilea Pharmaceutica AG
    Grenzacherstrasse 487 Basel Switzerland


    Listed: Freiverkehr in Börse Stuttgart,
    Freiverkehr in Börse Berlin,
    Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
    Freiverkehr in Bayerische Börse München;


    Seite 2 von 2



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Basilea Pharmaceutica AG Continued strong Cresemba (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea - Seite 2 Basilea Pharmaceutica AG / Basilea Pharmaceutica AG : Continued strong Cresemba (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea . Processed and transmitted by West Corporation. The issuer is solely …

    Schreibe Deinen Kommentar

    Disclaimer